|
Cyclenium, Haplogen team up in discovery collaboration
June 2015
EDIT CONNECT
SHARING OPTIONS:
SHERBROOKE, Quebec &
VIENNA, Austria—Pharmaceutical company Cyclenium Pharma Inc. has inked a research agreement
with Haplogen GmbH to discover novel pharmaceutical candidates in multiple disease areas. The two
companies will focus on certain antiviral Haplogen targets initially, and will phase-in additional targets in other therapeutic indications as research
progresses. Haplogen brings with it unique haploid genetics technology and experience in host target identification, validation and screening, while
Cyclenium can provide its CMRT Technology-derived QUEST Library and hit-to-lead optimization expertise.
“Cyclenium’s proprietary macrocyclic library appears ideal for use against the challenging antiviral and other targets identified using
our haploid genetics platform,” said Dr. Georg Casari, CEO of Haplogen. “We look forward to working with their experienced and successful
research team in progressing our drug discovery programs.”
Code: Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|